MARKET

RDY

RDY

Dr Reddys Labs
NYSE
71.14
+0.23
+0.32%
After Hours: 71.14 +0.01 +0.01% 16:00 04/19 EDT
OPEN
70.90
PREV CLOSE
70.91
HIGH
71.30
LOW
70.72
VOLUME
116.99K
TURNOVER
0
52 WEEK HIGH
77.72
52 WEEK LOW
52.74
MARKET CAP
11.85B
P/E (TTM)
18.89
1D
5D
1M
3M
1Y
5Y
Dr. Reddy’s Introduces Innovative IBS Digital Care Plan
TipRanks · 18h ago
Dr. Reddy’s Q4 and FY24 Financial Results Due
TipRanks · 21h ago
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
NASDAQ · 1d ago
India's Biocon developing its own version of Wegovy, clinical trial likely next year
India's Biocon developing its own version of Novo Nordisk's Wegovy, clinical trial likely year. Wall Street has forecast the market for obesity treatments reaching at least $100 billion by the end of the decade. Biocon is looking to grab a piece of the exploding weight-loss drug market.
Reuters · 1d ago
Dr. Reddy’s Faces Tax Demand; Plans Appeal
TipRanks · 1d ago
Dr. Reddy’s Divests Venezuelan Subsidiary Stake
Dr. Reddy’s Laboratories Ltd. Has announced the sale of its entire stake in its Venezuelan subsidiary. The Venezuelan subsidiary had no turnover and a negative net worth in the last financial year. The transaction is expected to be completed by April 17, 2024. RDY stock is down 2% in the past week.
TipRanks · 4d ago
Weekly Report: what happened at RDY last week (0408-0412)?
Weekly Report · 5d ago
Dr. Reddy’s Debuts Migraine Device in Europe
TipRanks · 04/11 08:42
More
About RDY
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Webull offers Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE: RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.